Holen Sie sich die Stockscreener-App
10.85
0.37%
-0.04
Handel nachbörslich:
10.86
0.010
+0.09%
Ocular Therapeutix Inc Aktie (OCUL) Neueste Nachrichten
Ocular Therapeutix, Inc. (OCUL) Stock Analysis: Biotechnology Innovator with 122% Upside Potential - directorstalkinterviews.com
Responsive Playbooks and the OCUL Inflection - Stock Traders Daily
A Look Back at Pharmaceuticals Stocks’ Q3 Earnings: Ocular Therapeutix (NASDAQ:OCUL) Vs The Rest Of The Pack - Yahoo Finance
Decliners Report: Is Ocular Therapeutix Inc undervalued by DCF analysisJuly 2025 Sentiment & Detailed Earnings Play Alerts - baoquankhu1.vn
Corticosteroids Market Report 2026 - GlobeNewswire Inc.
A Look Back at Pharmaceuticals Stocks' Q3 Earnings: Ocular Therapeutix (NASDAQ:OCUL) Vs The Rest Of The Pack - Finviz
Bearish Setup: Whats Ocular Therapeutix Incs historical return2025 Historical Comparison & Precise Entry and Exit Recommendations - baoquankhu1.vn
Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - manilatimes.net
Ocular Therapeutix (NASDAQ:OCUL) Shares Down 5.9%What's Next? - MarketBeat
Ocular Therapeutix appoints Jason Robins as interim CFO during Notman’s leave By Investing.com - Investing.com India
Ocular Therapeutix appoints Jason Robins as interim CFO during Notman’s leave - Investing.com India
Ocular Therapeutix, Inc. Announces Chief Financial Officer Changes, Effective January 20, 2026 - marketscreener.com
Ocular Therapeutix appoints Jason Robins interim CFO - TipRanks
Ocular Therapeutix IncCFO Donald Notman takes medical leaveSEC filing - marketscreener.com
Ocular Therapeutix Names David W. Robinson as Global Chief Commercial Officer - VisionMonday.com
Hiring Retina Veteran as Global CCO Might Change The Case For Investing In Ocular Therapeutix (OCUL) - simplywall.st
Ocular Therapeutix appoints David Robinson as global chief commercial officer - Investing.com Nigeria
Ocular Therapeutix names David Robinson as global CCO - The Pharma Letter
Ocular Therapeutix Appoints David W. Robinson as Global Chief Commercial Officer - citybiz
Ocular Therapeutix hires veteran to lead commercial push for eye drugs; shares up - TradingView
Piper Sandler Maintains Ocular Therapeutix(OCUL.US) With Buy Rating, Maintains Target Price $31 - 富途资讯
Ocular Therapeutix Announces Appointment of David W. Robinson as Global Chief Commercial Officer - Quiver Quantitative
Ocular Therapeutix™ Appoints David W. Robinson as Global Chief Commercial Officer - manilatimes.net
Executive behind EYLEA launch to steer Ocular’s next eye drug AXPAXLI - Stock Titan
How sensitive is Ocular Therapeutix Inc to inflationJuly 2025 Sentiment & Reliable Breakout Stock Forecasts - baoquankhu1.vn
Can Ocular Therapeutix Inc sustain its profitabilityWeekly Investment Report & Safe Entry Momentum Stock Tips - baoquankhu1.vn
Will Ocular Therapeutix Inc benefit from geopolitical trendsEarnings Risk Report & Verified Technical Trade Signals - baoquankhu1.vn
CEO Change: Will Ocular Therapeutix Inc benefit from geopolitical trendsMarket Performance Summary & Expert Verified Movement Alerts - baoquankhu1.vn
Aug Breakouts: Is Ocular Therapeutix Inc gaining market shareJuly 2025 Snapshot & Capital Efficient Trade Techniques - baoquankhu1.vn
Peering Into Ocular Therapeutix Inc's Recent Short Interest - Sahm
Ocular Therapeutix Sees Unusually Large Options Volume (NASDAQ:OCUL) - MarketBeat
Ocular Therapeutix (OCUL) Valuation Check After Mixed Recent Returns And AXPAXLI Expectations - Yahoo Finance
Speculation of Sanofi Takeover Sends Ocular’s Stock Soaring - BioSpace
BRIEF—Sanofi reportedly eyeing bid for Ocular Therapeutix - The Pharma Letter
Understanding the Setup: (OCUL) and Scalable Risk - Stock Traders Daily
Ocular Launches, And Then Yo-Yoes, On Rumors Sanofi Is Preparing A Bigger Bid - MSN
Ocular Therapeutix (OCUL) Shares Surge Over 11% - GuruFocus
Ocular Therapeutix, Inc. (OCUL): A Bull Case Theory - Finviz
Sanofi (SNY) Plans Enhanced Offer for Ocular Therapeutix - GuruFocus
Ocular Therapeutix (NASDAQ:OCUL) Shares Gap UpTime to Buy? - MarketBeat
Why Sanofi May Need To Top $2.4 Billion For Ocular Therapeutix (NASDAQ:SNY) - Seeking Alpha
Ocular Therapeutix Target of Unusually High Options Trading (NASDAQ:OCUL) - MarketBeat
Ocular Therapeutix Shares Surge Following Reports Of Stronger Sanofi Bid - Benzinga
Ocular Therapeutix (OCUL) Surges on Potential Sanofi Takeover Bi - GuruFocus
RBC Capital Increases Price Target for OCUL Stock Amid Optimism - StocksToTrade
Ocular Therapeutix shares rise 11.1% - marketscreener.com
Strength Seen in Ocular Therapeutix (OCUL): Can Its 6.1% Jump Turn into More Strength? - Yahoo Finance
RBC Raises Ocular Therapeutix Price Target Amid Positive Outlook - timothysykes.com
Ocular surges on report of Sanofi buyout bid - Seeking Alpha
Why Is Ocular Therapeutix (OCUL) Stock Up Premarket Today? Sanofi Bid Rejection Fuels Rally - Tokenist
Ocular Therapeutics Awaits Wet AMD Trial Data, Stock Up Over 23% - Nasdaq
OCUL Stock Back On Retail Radar With Sanofi Takeover Speculation Resurfacing - Stocktwits
Sanofi readies higher bid for Ocular Therapeutix after initial rejectionreport - Investing.com Canada
Sanofi makes fresh play for Ocular Therapeutix - La Lettre
Is It Time To Reassess Ocular Therapeutix (OCUL) After Recent Share Price Volatility? - simplywall.st
2.09%
0.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):